Hepatitis B virus X upregulates HuR protein level to stabilize HER2 expression in hepatocellular carcinoma cells

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Hung, Chao Ming ^a   Huang, Wei Chien ^b,c,d   Pan, Hsiao Lin ^a   Chien, Pei Hsuan ^a   Lin, Chih Wen ^a,e   Chen, Lei Chin ^a   Chien, Yu Fong ^a   Lin, Ching Chiao ^a   Leow, Kar Hee ^a   Chen, Wen Shu ^b   Chen, Jhen Yu ^c   Ho, Chien Yi ^b   Hou, Pao Sheng ^a   Chen, Yun Ju ^a  

^a I SHOU UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; DACTINOMYCIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEPATITIS B VIRUS X PROTEIN; HUR PROTEIN; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; RNA BINDING PROTEIN; UVOMORULIN; ERBB2 PROTEIN, HUMAN; HU ANTIGEN; RNA; TRANSACTIVATOR PROTEIN;

ARTICLE; CANCER GROWTH; CARCINOMA CELL; CELL GROWTH ASSAY; CELL MIGRATION; CELL MIGRATION ASSAY; CELL STRAIN HEPG2; CONTROLLED STUDY; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; PLEIOTROPY; PROTEIN EXPRESSION; PROTEIN STABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA STABILITY; VIRUS CARCINOGENESIS; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; LIVER TUMOR; METABOLISM; PATHOLOGY; UPREGULATION; VIROLOGY;

GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HEPATITIS B VIRUS; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; LIVER NEOPLASMS; RECEPTOR, ERBB-2; RNA STABILITY; RNA, MESSENGER; RNA, NEOPLASM; TRANS-ACTIVATORS; UP-REGULATION;

EID: 84897830967     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/827415     Document Type: Article

References (48)

1. Donato F., Boffetta P., Puoti M., A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. International Journal of Cancer 1998 75 3 347 354 (Pubitemid 28100034)
2. Llovet J. M., Burroughs A., Bruix J., Hepatocellular carcinoma. The Lancet 2003 362 9399 1907 1917 2-s2.0-0141491273 10.1016/S0140-6736(03)14964-1 (Pubitemid 37518510)
3. Raza S. A., Clifford G. M., Franceschi S., Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. British Journal of Cancer 2007 96 7 1127 1134 2-s2.0-34247279672 10.1038/sj.bjc.6603649 (Pubitemid 46608308)
4. Fung J., Lai C.-L., Yuen M.-F., Hepatitis B and C virus-related carcinogenesis. Clinical Microbiology and Infection 2009 15 11 964 970 2-s2.0-70449134824 10.1111/j.1469-0691.2009.03035.x
5. Ryu W.-S., Molecular aspects of hepatitis B viral infection and the viral carcinogenesis. Journal of Biochemistry and Molecular Biology 2003 36 1 138 143 2-s2.0-0038205418 (Pubitemid 36836265)
6. Kew M. C., Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2011 26 1 144 152 2-s2.0-78650769017 10.1111/j.1440-1746.2010.06546.x
7. Ng S.-A., Lee C., Hepatitis B virus X gene and hepatocarcinogenesis. Journal of Gastroenterology 2011 46 8 974 990 2-s2.0-80052411388 10.1007/s00535-011-0415-9
8. Shih W.-L., Kuo M.-L., Chuang S.-E., Cheng A.-L., Doong S.-L., Hepatitis B virus X protein activates a survival signaling by linking Src to phosphatidylinositol 3-kinase. Journal of Biological Chemistry 2003 278 34 31807 31813 2-s2.0-0042357131 10.1074/jbc.M302580200 (Pubitemid 37048362)
9. Cha M.-Y., Kim C.-M., Park Y.-M., Ryu W.-S., Hepatitis B virus X protein is essential for the activation of Wnt/ β -catenin signaling in hepatoma cells. Hepatology 2004 39 6 1683 1693 2-s2.0-2542546650 10.1002/hep.20245 (Pubitemid 38702670)
10. Marmor M. D., Skaria K. B., Yarden Y., Signal transduction and oncogenesis by ErbB/HER receptors. International Journal of Radiation Oncology Biology Physics 2004 58 3 903 913 2-s2.0-1242315584 10.1016/j.ijrobp.2003.06.002 (Pubitemid 38221150)
11. Jung J. K., Kwun H. J., Lee J.-O., Arora P., Jang K. L., Hepatitis B virus X protein differentially effects the ubiquitin-mediated proteasomal degradation of β -catenin depending on the status of cellular p53. Journal of General Virology 2007 88 8 2144 2154 2-s2.0-34547600513 10.1099/vir.0.82836-0 (Pubitemid 47194209)
12. Liu H., Ye L., Wang Q.-W., Yan Q.-X., Yu J.-M., Effect of a conserved peptide derived from Kunitz domain of hepatitis B virus x protein on the cell cycle and apoptosis of HepG2 cells via the proteasome pathway. Chinese Medical Journal 2009 122 4 460 465 2-s2.0-65649135452 10.3760/cma.j.issn.0366-6999.2009. 04.0019
13. Tian Y., Yang W., Song J., Hepatitis B virus X protein-induced aberrant epigenetic modifications contributing to human hepatocellular carcinoma pathogenesis. Molecular and Cellular Biology 2013 33 15 2810 2816
14. Yarden Y., The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. European Journal of Cancer 2001 37 4 S3 S8 2-s2.0-0034773992 (Pubitemid 32938123)
15. Yu M.-W., Chen C.-J., Luo J.-C., Brandt-Rauf P. W., Carney W. P., Santella R. M., Correlations of chronic hepatitis B virus infection and cigarette smoking with elevated expression of neu oncoprotein in the development of hepatocellular carcinoma. Cancer Research 1994 54 19 5106 5110 2-s2.0-0027993121 (Pubitemid 24313485)
16. Liu J., Ahiekpor A., Li L., Li X., Arbuthnot P., Kew M., Feitelson M. A., Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer. International Journal of Cancer 2009 125 8 1894 1901 2-s2.0-70349256084 10.1002/ijc.24580
17. Pegram M. D., Konecny G., Slamon D. J., The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treatment and Research 2000 103 57 75 2-s2.0-0033651234
18. Matsui K., Sugimori K., Motomura H., Ejiri N., Tsukada K., Kitajima I., PEA3 cooperates with c-Jun in regulation of HER2/neu transcription. Oncology Reports 2006 16 1 153 158 2-s2.0-33750730239
19. Scott G. K., Marx C., Berger C. E., Saunders L. R., Verdin E., Schäfer S., Jung M., Benz C. C., Destabilization of ERBB2 transcripts by targeting 3′ untranslated region messenger RNA associated HuR and histone deacetylase-6. Molecular Cancer Research 2008 6 7 1250 1258 2-s2.0-51649126046 10.1158/1541-7786.MCR-07-2110
20. Götte M., MicroRNAs in breast cancer pathogenesis. Minerva Ginecologica 2010 62 6 559 571 2-s2.0-79952229944
21. Citri A., Kochupurakkal B. S., Yarden Y., The Achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 2004 3 1 51 60 2-s2.0-1942431966 (Pubitemid 40268587)
22. Ohta T., Fukuda M., Ubiquitin and breast cancer. Oncogene 2004 23 11 2079 2088 2-s2.0-1842486790 10.1038/sj.onc.1207371 (Pubitemid 38496737)
23. Huang W.-C., Chen W.-S., Chen Y.-J., Wang L.-Y., Hsu S.-C., Chen C.-C., Hung M.-C., Hepatitis B virus X protein induces IKK α nuclear translocation via Akt-Dependent phosphorylation to promote the motility of hepatocarcinoma cells. Journal of Cellular Physiology 2012 227 4 1446 1454 2-s2.0-84855720148 10.1002/jcp.22860
24. Lam P. B., Burga L. N., Wu B. P., Hofstatter E. W., Lu K. P., Wulf G. M., Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability. Molecular Cancer 2008 7, article no. 91 2-s2.0-61349151785 10.1186/1476-4598-7-91
25. Brennan C. M., Steitz J. A., HuR and mRNA stability. Cellular and Molecular Life Sciences 2001 58 2 266 277 2-s2.0-0035099573 (Pubitemid 32217358)
26. Hsia T. C., Tu C. Y., Chen Y. J., Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells. Mol Pharmacolno 2013 83 4 857 869
27. Srikantan S., Gorospe M., HuR function in disease. Frontiers in Bioscience 2012 17 1 189 205 2-s2.0-84860332384 10.2741/3921
28. Ménard S., Casalini P., Campiglio M., Pupa S. M., Tagliabue E., Role of HER2/neu in tumor progression and therapy. Cellular and Molecular Life Sciences 2004 61 23 2965 2978 2-s2.0-12144284842 10.1007/s00018-004-4277-7 (Pubitemid 40104594)
29. Johnston S. R. D., Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists. International Journal of Gynecological Cancer 2006 16 2 543 548 2-s2.0-33748775727 10.1111/j.1525-1438.2006.00692.x (Pubitemid 44410965)
30. Willis B. C., Borok Z., TGF- β -induced EMT: mechanisms and implications for fibrotic lung disease. American Journal of Physiology 2007 293 3 L525 L534 2-s2.0-34548411746 10.1152/ajplung.00163.2007 (Pubitemid 47358808)
31. Moasser M. M., The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007 26 45 6469 6487 2-s2.0-34547854801 10.1038/sj.onc.1210477 (Pubitemid 47530601)
32. Dent S., Oyan B., Honig A., HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials. Cancer Treatment Reviews 2013 39 6 622 631 10.1016/j.ctrv.2013.01.002
33. Nielsen D. L., Kumler I., Palshof J. A., Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast 2013 22 1 1 12
34. Del Mastro L., Lambertini M., Bighin C., Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. Expert Review of Anticancer Therapy 2012 12 11 1391 1405
35. Xian Z.-H., Zhang S.-H., Cong W.-M., Wu W.-Q., Wu M.-C., Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma. Journal of Clinical Pathology 2005 58 5 500 503 2-s2.0-18444416067 10.1136/jcp.2004.023556 (Pubitemid 40646870)
36. Hsu C., Huang C.-L., Hsu H.-C., Lee P.-H., Wang S.-J., Cheng A.-L., HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity. Cancer 2002 94 2 415 420 2-s2.0-0037080265 10.1002/cncr.10180 (Pubitemid 34081371)
37. Prange W., Schirmacher P., Absence of therapeutically relevant c-erbB-2 expression in human hepatocellular carcinomas. Oncology Reports 2001 8 4 727 730 2-s2.0-0035406028 (Pubitemid 33758112)
38. Niu Z.-S., Wang M., Expression of c-erbB-2 and glutathione S-transferase-pi in hepatocellular carcinoma and its adjacent tissue. World Journal of Gastroenterology 2005 11 28 4404 4408 2-s2.0-23244433372 (Pubitemid 41093962)
39. Chen X., Cheung S. T., So S., Fan S. T., Barry C., Higgins J., Lai K.-M., Ji J., Dudoit S., Ng I. O. L., Van de Rijn M., Botstein D., Brown P. O., Gene expression patterns in human liver cancers. Molecular Biology of the Cell 2002 13 6 1929 1939 2-s2.0-0035985214 10.1091/mbc.02-02-0023. (Pubitemid 34651483)
40. Neo S. Y., Leow C. K., Vega V. B., Long P. M., Islam A. F. M., Lai P. B. S., Liu E. T., Ren E. C., Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. Hepatology 2004 39 4 944 953 2-s2.0-1842532206 10.1002/hep.20105 (Pubitemid 38428933)
41. Huang W. C., Hung M. C., Beyond NF- B activation: nuclear functions of I B kinase α Journal of Biomedical Science 2013 20, article 3 1 13 10.1186/1423-0127-20-3
42. Yen C. J., Lin Y. J., Yen C. S., Hepatitis B virus X protein upregulates mTOR signaling through IKKbeta to increase cell proliferation and VEGF production in hepatocellular carcinoma. PLoS ONE 2012 7 7 e41931
43. Ding Q., Xia W., Liu J.-C., Yang J.-Y., Lee D.-F., Xia J., Bartholomeusz G., Li Y., Pan Y., Li Z., Bargou R. C., Qin J., Lai C.-C., Tsai F.-J., Tsai C.-H., Hung M.-C., Erk associates with and primes GSK-3 β for its inactivation resulting in upregulation of β -catenin. Molecular Cell 2005 19 2 159 170 2-s2.0-22544433759 10.1016/j.molcel.2005.06.009 (Pubitemid 41019664)
44. Zhang L., Yang L., Liu X., MicroRNA-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through nuclear factor kappa B pathways. Hepatology 2013 57 5 1919 1930 10.1002/hep.26162
45. Chen Y.-J., Chien P.-H., Chen W.-S., Hepatitis B virus-encoded X protein downregulates EGFR expression via inducing microRNA-7 in hepatocellular carcinoma cells. Evidence-Based Complementary and Alternative Medicine 2013 2013 10 10.1155/2013/682380 682380
46. Wu C. S., Yen C. J., Chou R. H., Downregulation of microRNA-15b by hepatitis B virus X enhances hepatocellular carcinoma proliferation via fucosyltransferase 2-induced Globo H expression. International Journal of Cancer 2013 134 7 1638 1647 10.1002/ijc.28501
47. Srikantan S., Tominaga K., Gorospe M., Functional interplay between RNA-binding protein HuR and microRNAs. Current Protein and Peptide Science 2012 13 4 372 379
48. Kedde M., Agami R., Interplay between microRNAs and RNA-binding proteins determines developmental processes. Cell Cycle 2008 7 7 899 903 2-s2.0-42449141484 (Pubitemid 351573784)